Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Epistem diagnostic test cleared for Hepatitis C trials

The Institut’s approval allows clinical trials of the HCV test to commence
Epistem diagnostic test cleared for Hepatitis C trials
Genedrive detects viral RNA, covers all HCV genotypes and is performed at "point of need" medical centres

-- adds detail, share price --

Epistem Holdings’ (LON:EHP) genedrive diagnostic test has been cleared for clinical trials in Hepatitis C (HCV) by the Institut Pasteur in  Paris.

The qualitative HCV test was developed in collaboration with Inserm, the French National Institute of Health and Medical Research, under a €6m EU supported programme.

The Institut’s approval allows clinical trials of the HCV test to commence in anticipation of regulatory approval and market launch in the EU during 2017, Epistem said.

Ian Gilham, chairman said: "The commencement of clinical trials of our HCV assay is an important step in our ongoing commercialisation of Genedrive, alongside the introduction of our TB test into the Indian market.

“The excellent results seen with HCV serve as a key proof of principle of our ability to develop blood-based tests and allow us to proceed with the development of tests for Hepatitis B and HIV, positioning Genedrive as the point of care platform of choice for the diagnosis of infectious diseases." 

Genedrive detects viral RNA, covers all HCV genotypes and is performed at "point of need" medical centres directly on plasma within 90 minutes.

It is also a qualitative test, not a simple yes or no. This ability to measure the viral load is key for physicians as a new range of anti-viral drugs hits the market, said Gilham.

 An estimated 150 - 200mln people are believed to have chronic HCV viral infection with 350,000 deaths each year from related diseases.

Shares rose 7% to 120p.

 

PhilW.jpg
Why Invest In Epistem Holdings Plc? Read More Here

Register here to be notified of future EHP Company articles
View full EHP profile

Epistem Holdings Plc Timeline

Newswire
February 19 2016
Newswire
January 13 2016

Related Articles

Lab_56a610b229ca5.jpg
January 25 2016
Broker N+1 Singer said: “The licensing agreement with a large US biotech is excellent news and illustrates the commercial potential of Abzena’s ThioBridge platform for the design of better antibody-drug conjugate drugs.”
Cancer
May 02 2016
As UK biotechs are beating a trail to the US craving greater understanding and higher valuation, Doerfler and his team have opted to go in the opposite direction.
Test-tubes_opt_56d69b8aa24bf.jpg
March 02 2016
The company's results reveal a company in rude health - and one still on the acquisition trial.

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.